inVentiv Health (inVentiv), a life science knowledge and services company, and specialty pharmaceutical company, Aprecia Pharmaceuticals (Aprecia), have formed an exclusive sales and marketing alliance.

This partnership will launch the Aprecia brand, as well as provide comprehensive commercialization of Aprecia’s pioneering technology platform and initial pharmaceutical products.

Aprecia is the first and only pharmaceutical company offering the proprietary ZipDose product platform using three-dimensional printing (3DP) technology to create fast-melt products. These products promise to change how patients experience taking their medicine by making drugs easier to administer and swallow. Aprecia has completed clinical work and expects to file its first New Drug Application with the Food and Drug Administration (FDA) in the second half of 2014.

inVentiv Health has directly supported the development and/or commercialization of 60 percent of all drugs approved by the FDA in the last 5 years. By partnering with inVentiv, Aprecia gains access to the industry’s only full commercialization outsourcing organization.

Under the terms of the agreement, inVentiv will partner with Aprecia as its exclusive provider of comprehensive commercialization services and will share in the success of the commercialization efforts. inVentiv will invest time and materials to launch Aprecia and to commercialize its products in exchange for a negotiated royalty from future sales. inVentiv’s services include: sales teams and sales training, strategic and tactical market access services, non-personal promotion, advertising, public relations, adherence services, and full management of the commercialization teams.

“Getting medicine into the human body reliably and accurately is both a challenge and an enormous opportunity,” said Don Wetherhold, chief executive officer of Aprecia. “To realize the potential of our technology and move quickly into market, we sought a partner that could execute every phase and function in commercialization -- and inVentiv was the obvious choice.”

Wetherhold added that with access to inVentiv’s vast commercial services, “Aprecia anticipates achieving rapid market penetration while retaining control of our proprietary products.”

Michael Griffith, executive vice president of inVentiv Health, said,“inVentiv Health offers innovative companies a unique outsourcing model for comprehensive commercialization.”

“We are pleased to have entered into this agreement with Aprecia and are looking forward to introducing their innovative technology platform and their much-needed products. Because of our unmatched expertise of pharmaceutical launches, clients know they can count on inVentiv Health to transform their assets into commercial success,” Griffith said.

Aprecia is a unique specialty pharmaceutical company built upon an innovative and proprietary three dimensional printing (3DP) technology platform.

inVentiv Health, Inc. is a life science knowledge and services company purpose-built for the new healthcare marketplace. inVentiv has created a new model by converging a vast range of essential services to fully align with our client's development and commercialization goals.